Immunogenicity and Safety of a New Meningococcal A Conjugate Vaccine in Indian Children Aged 2-10 Years: A Phase II/III Double-Blind Randomized Controlled Trial

This article, published in Vaccine, describes a study that compared the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac™, Serum Institute of India Ltd.) against the meningococcal group A component of a licensed quadrivalent meningococcal polysaccharide vaccine (PsACWY, Mencevax ACWY®, GlaxoSmithKline) 28 days after vaccination in Indian children. The article concludes that MenAfriVac™ is well tolerated and significantly more immunogenic when compared to the licensed polysaccharide vaccine in 2- to 10-year-old Indian children. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Follow the VRL

Free access to journal articles for users in the developing world

Some resources in the VRL require a subscription to view the full text. The World Health Organization’s (WHO) Health InterNetwork Access to Research Initiative (HINARI) provides free or very low cost online access to the major journals in biomedical and related social sciences to local, not-for-profit institutions in developing countries.